<DOC>
	<DOCNO>NCT03034135</DOCNO>
	<brief_summary>This study DSF-Cu combination TMZ recurrent GBM evaluate antitumor effect patient recurrent GBM . Patients take DSF-Cu daily routine standard care TMZ therapy approximately 6 month . Patients evaluate response every 8 week . Patients follow 2 year last dose DSF-Cu .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Disulfiram Copper Gluconate Recurrent Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Copper</mesh_term>
	<mesh_term>Disulfiram</mesh_term>
	<criteria>Histologically confirm GBM ( WHO grade IV ) . The subject must complete RT concurrent TMZ least 12 week prior plan start treatment study UNLESS pathological verification recurrent tumor least 4 week elapse since end RT concurrent TMZ . Experienced first unequivocal progression tumor magnetic resonance imaging ( MRI ) [ assess via Radiologic Assessment NeuroOncology ( RANO ) criterion within 3 month last dose TMZ . Karnofsky performance status ( KPS ) least 60 % . Willing remain abstinent consume alcohol . Recovered toxic effect prior therapy &lt; grade 2 toxicity per NCI CTCAE prior study registration ( except lymphopenia ) . Meets laboratory criterion follow parameter : ANC , platelet , hemoglobin , total bilirubin , alkaline phosphatase , aspartate aminotransferase , alanine aminotransferase , BUN creatinine . 11 . Females childbearing potential must willing use acceptable method birth control ( i.e. , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Radiographic evidence leptomeningeal dissemination , gliomatosis cerebri , infratentorial tumor , disease site remote supratentorial brain . Enrolled another clinical trial test novel therapy drug within past 4 week . Received one course radiation therapy total dose 75 Gy . History allergic reaction/hypersensitivity temozolomide , dacarbazine , DSF Cu . Treatment follow medication contraindicate DSF : metronidazole , isoniazid , dronabinol , carbocisteine , lopinavir , paraldehyde , ritonavir , sertraline , tindazole , tizanidine , atazanavir . Fever within 3 day prior study enrollment . Active severe hepatic renal disease . Grade 2 high peripheral neuropathy ataxia per NCI CTCAE History idiopathic seizure disorder schizophrenia , psychosis unrelated glioblastoma , corticosteroid , antiepileptic medication . History Wilson 's disease . History hemochromatosis . Pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>